Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more
Adocia (ADOC) - Net Assets
Latest net assets as of June 2025: €-617.00K EUR
Based on the latest financial reports, Adocia (ADOC) has net assets worth €-617.00K EUR as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€27.24 Million) and total liabilities (€27.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-617.00K |
| % of Total Assets | -2.27% |
| Annual Growth Rate | N/A |
| 5-Year Change | -148.77% |
| 10-Year Change | -106.57% |
| Growth Volatility | 500.49 |
Adocia - Net Assets Trend (2008–2024)
This chart illustrates how Adocia's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Adocia (2008–2024)
The table below shows the annual net assets of Adocia from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €-3.09 Million | +55.32% |
| 2023-12-31 | €-6.91 Million | +46.69% |
| 2022-12-31 | €-12.97 Million | +6.12% |
| 2021-12-31 | €-13.81 Million | -318.11% |
| 2020-12-31 | €6.33 Million | -77.41% |
| 2019-12-31 | €28.04 Million | -38.84% |
| 2018-12-31 | €45.85 Million | +24.40% |
| 2017-12-31 | €36.86 Million | -13.81% |
| 2016-12-31 | €42.76 Million | -9.12% |
| 2015-12-31 | €47.05 Million | +1778.32% |
| 2014-12-31 | €2.50 Million | -86.91% |
| 2013-12-31 | €19.13 Million | -16.93% |
| 2012-12-31 | €23.03 Million | +431.82% |
| 2011-12-31 | €4.33 Million | -59.48% |
| 2010-12-31 | €10.69 Million | -7.11% |
| 2009-12-31 | €11.51 Million | +91.24% |
| 2008-12-31 | €6.02 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adocia's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 932100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €1.57 Million | % |
| Other Comprehensive Income | €-25.20 Million | % |
| Other Components | €29.86 Million | % |
| Total Equity | €-3.09 Million | 100.00% |
Adocia Competitors by Market Cap
The table below lists competitors of Adocia ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Champion Microelectronic Corp
TW:3257
|
$84.59 Million |
|
De Licacy Industrial Co Ltd
TW:1464
|
$84.59 Million |
|
Powercell Sweden
ST:PCELL
|
$84.61 Million |
|
NIVIKA FASTIGHETER AB
F:Y5R
|
$84.62 Million |
|
Briscoe Group Australasia Ltd
AU:BGP
|
$84.57 Million |
|
Taiwan Optical Platform Co Ltd
TW:6464
|
$84.55 Million |
|
HUSCOMPAGNIET A/S DK 5
F:HCE
|
$84.49 Million |
|
Bookook Securities Co Ltd
KO:001275
|
$84.47 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adocia's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -6,914,000 to -3,090,000, a change of 3,824,000.
- Net loss of 9,321,000 reduced equity.
- Share repurchases of 12,083,000 reduced equity.
- New share issuances of 12,083,000 increased equity.
- Other comprehensive income increased equity by 1,400,000.
- Other factors increased equity by 11,745,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-9.32 Million | -301.65% |
| Share Repurchases | €12.08 Million | -391.04% |
| Share Issuances | €12.08 Million | +391.04% |
| Other Comprehensive Income | €1.40 Million | +45.31% |
| Other Changes | €11.74 Million | +380.1% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Adocia's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €2.65 | €5.83 | x |
| 2011-12-31 | €0.97 | €5.83 | x |
| 2012-12-31 | €3.85 | €5.83 | x |
| 2013-12-31 | €3.08 | €5.83 | x |
| 2014-12-31 | €0.40 | €5.83 | x |
| 2015-12-31 | €6.75 | €5.83 | x |
| 2016-12-31 | €6.25 | €5.83 | x |
| 2017-12-31 | €5.37 | €5.83 | x |
| 2018-12-31 | €6.02 | €5.83 | x |
| 2019-12-31 | €4.04 | €5.83 | x |
| 2020-12-31 | €0.91 | €5.83 | x |
| 2021-12-31 | €-1.96 | €5.83 | x |
| 2022-12-31 | €-1.61 | €5.83 | x |
| 2023-12-31 | €-0.62 | €5.83 | x |
| 2024-12-31 | €-0.20 | €5.83 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adocia utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -100.01%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-100.11%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -44.27% | -4262.16% | 0.01x | 1.41x | €-5.80 Million |
| 2011 | -149.05% | -416.12% | 0.09x | 4.07x | €-6.89 Million |
| 2012 | -26.03% | -150.03% | 0.11x | 1.59x | €-8.30 Million |
| 2013 | -22.44% | -76.81% | 0.23x | 1.29x | €-6.21 Million |
| 2014 | -826.95% | -2942.47% | 0.01x | 20.98x | €-20.97 Million |
| 2015 | 26.68% | 33.99% | 0.42x | 1.87x | €7.85 Million |
| 2016 | -18.46% | -35.09% | 0.29x | 1.84x | €-12.17 Million |
| 2017 | -23.20% | -43.92% | 0.36x | 1.46x | €-12.24 Million |
| 2018 | 16.61% | 16.07% | 0.68x | 1.53x | €3.03 Million |
| 2019 | -66.34% | -868.08% | 0.03x | 2.21x | €-21.41 Million |
| 2020 | -368.23% | -2773.37% | 0.02x | 7.13x | €-23.96 Million |
| 2021 | 0.00% | -1575.76% | 0.05x | 0.00x | €-21.37 Million |
| 2022 | 0.00% | -60.29% | 0.37x | 0.00x | €-5.60 Million |
| 2023 | 0.00% | -984.28% | 0.09x | 0.00x | €-20.47 Million |
| 2024 | 0.00% | -100.01% | 0.34x | 0.00x | €-9.01 Million |
Industry Comparison
This section compares Adocia's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $13,431,915
- Average return on equity (ROE) among peers: -56.94%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adocia (ADOC) | €-617.00K | -44.27% | N/A | $84.57 Million |
| Abionyx Pharma SA (ABNX) | $8.89 Million | -56.01% | 1.06x | $72.33 Million |
| Abivax SA (ABVX) | $56.72 Million | -25.23% | 0.07x | $3.97 Billion |
| Aelis Farma SA (AELIS) | $898.00K | 63.92% | 30.53x | $5.01 Million |
| Acticor Biotech SAS (ALACT) | $-4.04 Million | 0.00% | 0.00x | $2.13 Million |
| NicOx S.A. (ALCOX) | $21.41 Million | -97.51% | 1.47x | $28.49 Million |
| Advicenne (ALDVI) | $-1.67 Million | 0.00% | 0.00x | $15.84 Million |
| ALGAE (ALGAE) | $32.76 Million | -39.31% | 0.56x | $29.13 Million |
| Genoway (ALGEN) | $5.23 Million | 9.60% | 1.10x | $23.45K |
| Integragen (ALINT) | $691.87K | -367.93% | 7.36x | $424.10K |